Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.

Wasir JS, Mithal A, Agarwal P, Mittal A

Indian journal of endocrinology and metabolism1 Nov 2018Cited by 6 (Europe PMC)

PMID30766809PMCIDPMC6330857DOI10.4103/ijem.ijem_424_18PepBankPUB-30766809

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In Indian patients with T2DM, dulaglutide was linked to a mean HbA1c reduction of 0.87% from baseline.
In plain wordsIn Indian patients with T2DM, dulaglutide was linked to a mean HbA1c reduction of 0.87% from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction
Study
n = 74
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
HbA1c mean reduction
0.87%
6 months
Source sentences
Summary
Final analysis was done on complete data of 74 patients (6 months follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 months of: HbA1c; 0.87% and weight; 3.8 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
Report a problemFND-3076680901
02HumanObservational studyEfficacy outcome
In Indian patients with T2DM, dulaglutide was linked to a mean weight reduction of 3.8 kg from baseline.
In plain wordsIn Indian patients with T2DM, dulaglutide was linked to a mean weight reduction of 3.8 kg from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight reduction
Study
n = 74
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight mean reduction
3.8 kg
6 months
Source sentences
Summary
Final analysis was done on complete data of 74 patients (6 months follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 months of: HbA1c; 0.87% and weight; 3.8 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
Report a problemFND-3076680902
03HumanObservational studySafety outcome
In Indian patients with T2DM receiving dulaglutide, nausea was reported in 15%.
In plain wordsIn Indian patients with T2DM receiving dulaglutide, nausea was reported in 15%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Nausea
15%
dulaglutide-treated patients
Source sentences
Summary
The most common side-effects were gastrointestinal (15% nausea and 6% loose motions).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
Report a problemFND-3076680905
04HumanObservational studySafety outcome
In Indian patients with T2DM receiving dulaglutide, loose motions were reported in 6%.
In plain wordsIn Indian patients with T2DM receiving dulaglutide, loose stools were reported in 6%.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableLoose motions
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Loose motions
6%
dulaglutide-treated patients
Source sentences
Summary
The most common side-effects were gastrointestinal (15% nausea and 6% loose motions).
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
Report a problemFND-3076680906
05HumanObservational studySafety outcome
In Indian patients with T2DM, 25% discontinued dulaglutide because of gastrointestinal side-effects.
In plain wordsIn Indian patients with T2DM, 25% stopped dulaglutide because of digestive side-effects.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiscontinuation for gastrointestinal effects
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Discontinuation for gastrointestinal side-effects
25%
dulaglutide-treated patients
Discontinuation for gastrointestinal side-effects
19 participants
dulaglutide-treated patients
Source sentences
Summary
Also, 25% (n = 19) of our study subjects discontinued dulaglutide because of gastrointestinal side-effects.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
Report a problemFND-3076680907

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Indian patients receiving dulaglutide, poorer initial glycemic control was linked to a larger HbA1c fall than better initial control.
In plain wordsIn Indian patients receiving dulaglutide, poorer initial blood sugar control was linked to a larger HbA1c fall than better initial control.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBaseline HbA1c association with response
Study
n = 74
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Subjects with a poorer glycemic control (greater HbA1c) or greater weight at initiation had a better fall in HbA1c and weight reduction at the end of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3076680903
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In Indian patients receiving dulaglutide, greater initial weight was linked to greater weight reduction than lower initial weight.
In plain wordsIn Indian patients receiving dulaglutide, greater initial weight was linked to greater weight reduction than lower initial weight.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBaseline weight association with response
Study
n = 74
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Subjects with a poorer glycemic control (greater HbA1c) or greater weight at initiation had a better fall in HbA1c and weight reduction at the end of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3076680904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.